Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block and Reserpine in Group 2 Pulmonary Hypertension
NCT02684786Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jul 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of reserpine in pulmonary hypertension (PH), sponsored by Mayo Clinic. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 1 month. Planned start Jul 2016; status: withdrawn.
02
Drugs
reserpine
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02684786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684786.